肩峰下撞擊症候群市場 - 全球產業規模、佔有率、趨勢、機會及預測（按肌肉骨骼疾病類型、診斷和影像技術、治療方法、最終用戶、地區和競爭格局分類，2021-2031年）

全球肩峰下撞擊症候群市場預計將從 2025 年的 87.2 億美元成長到 2031 年的 134.1 億美元，複合年成長率為 7.44%。

肩峰撞擊症候群是指肩關節內的滑囊或肌腱受到壓迫的一種疾病，其治療方法多種多樣，從藥物和物理治療等保守治療到關節鏡減壓手術均有涵蓋。市場成長的主要促進因素是老年人口的增加（老年人更容易患退化性結締組織疾病）以及因重複性過頂運動導致的運動傷害增加。這些關鍵因素正在持續推動對有效疼痛管理策略和旨在恢復患者功能性活動能力的整形外科解決方案的需求。

然而，由於擇期關節鏡手術費用高昂，以及可能限制患者獲得先進治療的報銷政策，市場成長面臨潛在障礙。此外，長期藥物治療的副作用也會使患者難以堅持保守治療方案。美國整形外科學會報告稱，2024年，該學會登記的肩迴旋肌手術中，有59%同時進行了肩峰下減壓手術，顯示該疾病的臨床病例量巨大。

市場促進因素

全球肩迴旋肌損傷和肩峰撞擊症候群的發生率不斷上升，這主要受人口快速老化的影響，也是推動市場擴張的主要因素。隨著老齡人口的成長，需要醫療干預的退化性結締組織疾病也隨之增加；同時，更年輕、更活躍的人群也面臨著因高舉過頭運動而導致的重複性勞損的日益普遍。這兩類患者的湧入持續推高了對整形外科修復解決方案的需求，直接提升了醫療設備製造商的收入。史賽克公司在2025年10月舉行的「2025年第三季財報電話會議」中重點強調了這一趨勢。該公司宣布，其整形外科部門實現了11.4%的內部成長，並將這一成功主要歸功於肩部護理產品的持續成長勢頭以及門診手術中心手術量的增加。

同時，微創關節關節鏡手術技術的進步正在改善臨床療效並擴大潛在患者群。符合人體工學的動力器械、無結固定裝置和高清可視化技術的創新，使外科醫生能夠以更小的組織損傷進行精準的肩峰下減壓手術，從而加快患者康復。這些進步不僅提高了手術效率，也縮短了手術器械的更換週期。例如，在2025年6月題為「Arthrex推出革命性動力器材系統」的新聞稿中，Arthrex宣布推出其Synergy動力系統，該系統增強了先進的關節置換和運動醫學技術。此類技術應用帶來的商業性影響在整個產業中顯而易見，CONMED在2025年11月發布的報告顯示，得益於強大的外科產品組合，其第三季銷售額年增6.7%至3.379億美元。

市場挑戰

嚴格的健保報銷政策和高昂的擇期關節鏡手術費用嚴重阻礙了肩峰撞擊症候群市場的發展。由於先進的手術治療缺乏足夠的健保覆蓋，患者往往需要承擔高額的自付費用，從而放棄或延後手術減壓。這種經濟負擔直接減少了手術介入的數量，並促使市場傾向於盈利較低的保守治療方法。這反過來又抑制了專用手術器械和相關整形外科解決方案的應用，從而限制了該行業的潛在成長。

此外，主要支付方報銷率的下降給醫療服務提供者造成了不永續的經濟環境，使他們無法優先考慮這些擇期手術。據美國整形外科醫師協會稱，2024年實施的聯邦醫療保險醫師收費標準將轉換係數降低了約3.4%，進一步壓縮了整形外科診所的營運利潤。報銷獎勵的持續減少迫使醫療機構整合服務或限制資源密集型肩峰下撞擊症候群手術方案的提供，阻礙了整體市場成長。

市場趨勢

生物誘導支架在肌腱修復中的日益廣泛應用，正從根本上改變治療通訊協定，因為它解決了肩迴旋肌手術中機械固定的生物學限制。與僅依賴組織對合的傳統縫合技術不同，這些生物誘導植入能夠促進自然癒合並增加肌腱厚度，從而降低因組織退化而導致的再次斷裂的高風險。這項臨床優勢促使其迅速商業性化，外科醫師擴大採用這些生物材料來加強結締組織薄弱患者的修復，並將其作為關節鏡減壓手術的輔助手段。例如，史密斯-內普公司在其2025年8月發布的「2025會計年度第二季/上半年收益報告」中指出，其REGENETEN生物誘導植入的銷售額實現了兩位數的強勁成長，這凸顯了運動醫學領域向生物強化療法的加速轉變。

同時，隨著醫療機構更加重視多模式鎮痛方法，旨在促進患者康復並減少鴉片類藥物依賴，非鴉片類術後鎮痛通訊協定的發展勢頭強勁。這一趨勢對於門診進行的肩峰下撞擊症候群手術尤其重要，因為長效局部麻醉劑能夠幫助患者早期活動和出院，且不會產生與麻醉性鎮痛藥相關的全身性副作用。市場上，緩釋脂質體Bupivacaine製劑的使用日益增多，這類製劑能夠直接在手術部位提供持續鎮痛，進而提高病患滿意度。為了佐證這一轉變，Pasira Biosciences公司於2025年11月宣布，其產品EXPAREL的淨銷售額達到1.399億美元，這主要得益於9%的銷量成長，也反映了非鴉片類術後鎮痛治療標準的不斷演進。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球肩峰下撞擊症候群市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依肌肉骨骼疾病類型（骨關節炎、類風濕性關節炎、骨質疏鬆症、背部和頸部疼痛、肩峰撞擊症候群、膝關節疼痛和疾病、髖關節疼痛和疾病、創傷和骨折、運動傷害、其他）
  • 透過診斷和影像技術（X光、磁振造影（MRI）、電腦斷層掃描（CT）、超音波、關節鏡檢查、其他）
  • 依治療方法（藥物治療、手術介入）
  • 按最終使用者（醫院/診所、門診護理中心、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美肩峰下撞擊症候群市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲肩峰下撞擊症候群市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區肩周炎市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲肩峰下撞擊症候群市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲肩峰撞擊症候群市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球肩峰下撞擊症候群市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Bioventus LLC
• Orthofix Medical Inc.
• Breg, Inc.
• ConMed Corporation
• Ossur hf.
• Arthrex, Inc.
• Globus Medical, Inc.
• NuVasive, Inc.
• Stryker Corporation
• Medtronic plc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Impingement Syndrome Market is projected to expand from a valuation of USD 8.72 Billion in 2025 to USD 13.41 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 7.44%. Defined as a pathological condition involving the compression of bursa or tendons within the shoulder joint, impingement syndrome necessitates treatments ranging from conservative measures like pharmaceuticals and physical therapy to arthroscopic surgical decompression. The market's growth is largely fueled by a growing elderly demographic prone to degenerative connective tissue issues and an increase in sports-related injuries resulting from repetitive overhead actions. These core drivers generate consistent demand for effective pain management strategies and orthopedic solutions aimed at restoring functional mobility in affected individuals.

Conversely, market growth faces potential hurdles due to the significant expenses linked to elective arthroscopic surgeries and restrictive reimbursement policies that may curtail patient access to advanced procedural care. Furthermore, adherence to conservative treatment plans can be compromised by the adverse effects associated with long-term medication use. Highlighting the substantial clinical volume of this condition, the American Academy of Orthopaedic Surgeons reported in 2024 that 59% of rotator cuff procedures entered into their registry involved concurrent subacromial decompression.

Market Driver

The escalating global incidence of rotator cuff disorders and shoulder impingement, significantly intensified by a rapidly aging population, acts as the primary catalyst for market expansion. As the elderly demographic grows, there is a parallel rise in degenerative connective tissue diseases requiring medical attention, while younger, active individuals increasingly suffer from repetitive strain injuries due to overhead sports. This twofold patient influx generates continuous demand for orthopedic repair solutions, directly enhancing revenue for medical device companies. This trend was illustrated by Stryker during their 'Q3 2025 Earnings Call' in October 2025, where the company announced that its orthopedics division attained 11.4% organic growth, a success largely ascribed to sustained momentum in shoulder care offerings and rising procedure volumes in ambulatory surgery centers.

Concurrently, technological progress in minimally invasive arthroscopic techniques is improving clinical results and widening the potential patient base. The innovation of ergonomic power instruments, knotless fixation devices, and high-definition visualization allows surgeons to execute precise subacromial decompressions with reduced tissue disruption, thereby hastening patient recovery. These advancements not only enhance procedural effectiveness but also stimulate the replacement cycle for surgical tools. For instance, in a June 2025 press release titled 'Arthrex Introduces Innovative Powered Instrument System', Arthrex debuted the Synergy Power System to bolster advanced arthroplasty and sports medicine techniques. The commercial influence of adopting such technology is apparent industry-wide; CONMED Corporation reported in November 2025 that it secured third-quarter sales of $337.9 million, marking a 6.7% year-over-year rise driven by its robust surgical portfolio.

Market Challenge

Restrictive reimbursement policies and the high costs attached to elective arthroscopic surgeries represent considerable obstacles to the growth of the impingement syndrome market. When financial coverage for advanced procedural care is constrained, patients encounter significant out-of-pocket costs, often leading them to decline or postpone surgical decompression. This lack of economic accessibility directly lowers the volume of surgical interventions, shifting market preference toward conservative, lower-cost therapies that yield lower revenue. As a result, the uptake of specialized surgical devices and related orthopedic solutions is suppressed, curbing the sector's potential financial expansion.

Moreover, decreasing reimbursement rates from major payers establish an unsustainable economic landscape for healthcare providers, dissuading the prioritization of these elective surgeries. According to the American Academy of Orthopaedic Surgeons, the 2024 implementation of the Medicare Physician Fee Schedule led to a conversion factor reduction of approximately 3.4 percent, which further squeezed operating margins for orthopedic practices. This ongoing reduction of reimbursement incentives compels medical facilities to consolidate services or restrict the availability of resource-heavy surgical options for impingement syndrome, thereby inhibiting the overall market trajectory.

Market Trends

The increasing use of bio-inductive scaffolds for tendon repair is fundamentally transforming treatment protocols by targeting the biological constraints of mechanical fixation in rotator cuff procedures. In contrast to conventional suture-only methods that depend solely on tissue approximation, these bio-inductive implants encourage natural healing and enhance tendon thickness, thereby alleviating the high re-tear risk linked to degenerative tissue quality. This clinical benefit is propelling rapid commercial adoption as surgeons increasingly employ these biologics to reinforce repairs and augment arthroscopic decompressions in patients with weak connective tissue. Highlighting this demand, Smith+Nephew reported in their 'Second Quarter and First Half 2025 Results' in August 2025 that they achieved strong double-digit revenue growth from their REGENETEN Bioinductive Implant, underscoring the accelerating transition toward biological augmentation in sports medicine.

Simultaneously, the advancement of non-opioid post-operative pain management protocols is gathering momentum as healthcare providers focus on multimodal analgesia to support recovery and reduce opioid reliance. This trend is especially pertinent for impingement syndrome surgeries conducted in outpatient settings, where long-acting local anesthetics facilitate earlier mobilization and discharge without the systemic side effects associated with narcotics. The market is observing rising usage of extended-release liposomal bupivacaine formulations that offer sustained pain relief directly at the surgical site, thereby boosting patient satisfaction scores. Demonstrating this shift, Pacira BioSciences announced in November 2025, within their 'Pacira BioSciences Reports Third Quarter 2025 Financial Results', that the company realized net product sales of $139.9 million for EXPAREL, driven by a 9% volume increase that reflects the evolving standard of care for non-opioid postsurgical pain control.

Key Market Players

• Bioventus LLC
• Orthofix Medical Inc.
• Breg, Inc.
• ConMed Corporation
• Ossur hf.
• Arthrex, Inc.
• Globus Medical, Inc.
• NuVasive, Inc.
• Stryker Corporation
• Medtronic plc

Report Scope

In this report, the Global Impingement Syndrome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Impingement Syndrome Market, By Type of Musculoskeletal Disorder

• Osteoarthritis
• Rheumatoid Arthritis
• Osteoporosis
• Back and Neck Pain
• Shoulder Impingement Syndrome
• Knee Pain and Disorders
• Hip Pain and Disorders
• Trauma and Fracture
• Sports Injuries
• Others

Impingement Syndrome Market, By Diagnosis and Imaging Techniques

• X-ray
• Magnetic Resonance Imaging (MRI)
• Computed Tomography (CT) Scan
• Ultrasound
• Arthroscopy
• Others

Impingement Syndrome Market, By Treatment Modalities

• Medications
• Surgical Interventions

Impingement Syndrome Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Impingement Syndrome Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Impingement Syndrome Market.

Available Customizations:

Global Impingement Syndrome Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Impingement Syndrome Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type of Musculoskeletal Disorder (Osteoarthritis, Rheumatoid Arthritis, Osteoporosis, Back and Neck Pain, Shoulder Impingement Syndrome, Knee Pain and Disorders, Hip Pain and Disorders, Trauma and Fracture, Sports Injuries, Others)
  • 5.2.2. By Diagnosis and Imaging Techniques (X-ray, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan, Ultrasound, Arthroscopy, Others)
  • 5.2.3. By Treatment Modalities (Medications, Surgical Interventions)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Impingement Syndrome Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type of Musculoskeletal Disorder
  • 6.2.2. By Diagnosis and Imaging Techniques
  • 6.2.3. By Treatment Modalities
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Impingement Syndrome Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type of Musculoskeletal Disorder
      • 6.3.1.2.2. By Diagnosis and Imaging Techniques
      • 6.3.1.2.3. By Treatment Modalities
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Impingement Syndrome Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type of Musculoskeletal Disorder
      • 6.3.2.2.2. By Diagnosis and Imaging Techniques
      • 6.3.2.2.3. By Treatment Modalities
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Impingement Syndrome Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type of Musculoskeletal Disorder
      • 6.3.3.2.2. By Diagnosis and Imaging Techniques
      • 6.3.3.2.3. By Treatment Modalities
      • 6.3.3.2.4. By End User

7. Europe Impingement Syndrome Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type of Musculoskeletal Disorder
  • 7.2.2. By Diagnosis and Imaging Techniques
  • 7.2.3. By Treatment Modalities
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Impingement Syndrome Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type of Musculoskeletal Disorder
      • 7.3.1.2.2. By Diagnosis and Imaging Techniques
      • 7.3.1.2.3. By Treatment Modalities
      • 7.3.1.2.4. By End User
  • 7.3.2. France Impingement Syndrome Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type of Musculoskeletal Disorder
      • 7.3.2.2.2. By Diagnosis and Imaging Techniques
      • 7.3.2.2.3. By Treatment Modalities
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Impingement Syndrome Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type of Musculoskeletal Disorder
      • 7.3.3.2.2. By Diagnosis and Imaging Techniques
      • 7.3.3.2.3. By Treatment Modalities
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Impingement Syndrome Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type of Musculoskeletal Disorder
      • 7.3.4.2.2. By Diagnosis and Imaging Techniques
      • 7.3.4.2.3. By Treatment Modalities
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Impingement Syndrome Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type of Musculoskeletal Disorder
      • 7.3.5.2.2. By Diagnosis and Imaging Techniques
      • 7.3.5.2.3. By Treatment Modalities
      • 7.3.5.2.4. By End User

8. Asia Pacific Impingement Syndrome Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type of Musculoskeletal Disorder
  • 8.2.2. By Diagnosis and Imaging Techniques
  • 8.2.3. By Treatment Modalities
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Impingement Syndrome Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type of Musculoskeletal Disorder
      • 8.3.1.2.2. By Diagnosis and Imaging Techniques
      • 8.3.1.2.3. By Treatment Modalities
      • 8.3.1.2.4. By End User
  • 8.3.2. India Impingement Syndrome Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type of Musculoskeletal Disorder
      • 8.3.2.2.2. By Diagnosis and Imaging Techniques
      • 8.3.2.2.3. By Treatment Modalities
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Impingement Syndrome Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type of Musculoskeletal Disorder
      • 8.3.3.2.2. By Diagnosis and Imaging Techniques
      • 8.3.3.2.3. By Treatment Modalities
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Impingement Syndrome Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type of Musculoskeletal Disorder
      • 8.3.4.2.2. By Diagnosis and Imaging Techniques
      • 8.3.4.2.3. By Treatment Modalities
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Impingement Syndrome Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type of Musculoskeletal Disorder
      • 8.3.5.2.2. By Diagnosis and Imaging Techniques
      • 8.3.5.2.3. By Treatment Modalities
      • 8.3.5.2.4. By End User

9. Middle East & Africa Impingement Syndrome Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type of Musculoskeletal Disorder
  • 9.2.2. By Diagnosis and Imaging Techniques
  • 9.2.3. By Treatment Modalities
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Impingement Syndrome Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type of Musculoskeletal Disorder
      • 9.3.1.2.2. By Diagnosis and Imaging Techniques
      • 9.3.1.2.3. By Treatment Modalities
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Impingement Syndrome Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type of Musculoskeletal Disorder
      • 9.3.2.2.2. By Diagnosis and Imaging Techniques
      • 9.3.2.2.3. By Treatment Modalities
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Impingement Syndrome Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type of Musculoskeletal Disorder
      • 9.3.3.2.2. By Diagnosis and Imaging Techniques
      • 9.3.3.2.3. By Treatment Modalities
      • 9.3.3.2.4. By End User

10. South America Impingement Syndrome Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type of Musculoskeletal Disorder
  • 10.2.2. By Diagnosis and Imaging Techniques
  • 10.2.3. By Treatment Modalities
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Impingement Syndrome Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type of Musculoskeletal Disorder
      • 10.3.1.2.2. By Diagnosis and Imaging Techniques
      • 10.3.1.2.3. By Treatment Modalities
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Impingement Syndrome Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type of Musculoskeletal Disorder
      • 10.3.2.2.2. By Diagnosis and Imaging Techniques
      • 10.3.2.2.3. By Treatment Modalities
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Impingement Syndrome Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type of Musculoskeletal Disorder
      • 10.3.3.2.2. By Diagnosis and Imaging Techniques
      • 10.3.3.2.3. By Treatment Modalities
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Impingement Syndrome Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bioventus LLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Orthofix Medical Inc.
• 15.3. Breg, Inc.
• 15.4. ConMed Corporation
• 15.5. Ossur hf.
• 15.6. Arthrex, Inc.
• 15.7. Globus Medical, Inc.
• 15.8. NuVasive, Inc.
• 15.9. Stryker Corporation
• 15.10. Medtronic plc

16. Strategic Recommendations

17. About Us & Disclaimer